ICON PLC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $ICLR in the last 7 days.
No SEC Form 4 filings for $ICLR in the last 30 days.
See all $ICLR insider activity →BofA Securities upgraded ICON Public Limited Co. (ICLR) to neutral from underweight, citing improved demand for contract research organization services. The bank expects R&D spending growth of ~4% for top 50 biopharma companies by 2027, enhancing visibility. ICLR shares may benefit from this trend, according to the report.
ICON plc (NASDAQ: ICLR) announced it will release Q3 2026 earnings after market close on Oct 27, 2026, followed by a conference call on Oct 28, 2026. The company is a leading clinical research organization with global operations. It also provided a list of risks and uncertainties that could impact its financial performance.
UBS resumed coverage of Icon PLC (ICLR) with a Neutral rating and $195 price target, citing sector growth but client-specific challenges. GuruFocus estimates ICLR's intrinsic value at $205.65, indicating a 17.2% undervaluation. The stock has a high GF Score of 94/100, with strong valuation and profitability but moderate financial strength. Insiders have sold $4.0M in shares over the past year.
Recent ICLR coverage spans insider activity, financial news and earnings.
Upgrade to neutral may lift sentiment and support price gains.
The announcement provides a schedule but contains no new financial data or guidance.
Analyst coverage restart and price target may drive modest upside pressure.
Fund exit may pressure ICON shares modestly.
Insider sale may signal weak confidence, modest downward pressure.
AlphAI scores every news story that mentions ICLR with an AI model for sentiment and relevance, and aggregates insider trades from ICON PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
BofA Securities upgraded ICON Public Limited Co. (ICLR) to neutral from underweight, citing improved demand for contract research organization services. The bank expects R&D spending growth of ~4% for top 50 biopharma companies by 2027, enhancing visibility. ICLR shares may benefit from this trend, according to the report.
1 min readICON plc (NASDAQ: ICLR) announced it will release Q3 2026 earnings after market close on Oct 27, 2026, followed by a conference call on Oct 28, 2026. The company is a leading clinical research organization with global operations. It also provided a list of risks and uncertainties that could impact its financial performance.
1 min readUBS resumed coverage of Icon PLC (ICLR) with a Neutral rating and $195 price target, citing sector growth but client-specific challenges. GuruFocus estimates ICLR's intrinsic value at $205.65, indicating a 17.2% undervaluation. The stock has a high GF Score of 94/100, with strong valuation and profitability but moderate financial strength. Insiders have sold $4.0M in shares over the past year.
2 min readMarram Investment Management's Q2 2026 letter reported a 2.7% quarterly return, with ICON Public Limited Company (ICLR) as a notable exit. The firm cited a shrinking moat and competitive industry dynamics as reasons for the departure. ICON, a clinical research organization, has a market cap of $13.08B and a 52-week range of $66.57 to $203.91, closing at $169.55 on September 21, 2026.
1 min readCLIMAX JOHN DR sold 5,005 shares of ICON PLC (ICLR) at $175.00 ($0.88M total) on 2026-09-16.
1 min readMcCague Eugene Pacelli sold 3,255 shares of ICON PLC (ICLR) at $175.00 ($0.57M total) on 2026-09-17.
1 min readMurphy Ronan Martin sold 5,005 shares of ICON PLC (ICLR) at $175.00 ($0.88M total) on 2026-09-17.
1 min readSimply Wall St says ICON Investments Six Designated Activity Company priced $2.15B of senior unsecured notes (maturing 2029-2036) to refinance a bridge facility, secured term loans and 5.809% secured notes due 2027. The deal releases collateral and subsidiary guarantees, moving ICON toward an unsecured capital structure. The article links this to margin compression and execution/cash generation risks.
5 min readWhitaker Anne Clem sold 841 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.14M total) across 4 trades on 2026-08-11.
2 min readO'Neill Julie sold 915 shares of ICON PLC (ICLR) at an average of $164.29 ($162.72–$165.51, $0.15M total) across 4 trades on 2026-08-11.
2 min read
